Browsing Tag
Heidelberg University
2 posts
Syntara’s (ASX: SNT) AZALOX trial clears first safety hurdle and advances to final 200 mg cohort
Syntara Limited has advanced its AZALOX study into the final Phase 1b cohort after the first patients completed treatment without dose-limiting toxicities, keeping a preliminary Q4 2026 data release on track.
Fusion Pharmaceuticals secures rights for advanced prostate cancer treatment from Heidelberg University and Euratom
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a trailblazer in the oncology sector specializing in the development of next-generation radiopharmaceuticals,…